Comparison of Two Ultrasmall Superparamagnetic Iron Oxides on Cytotoxicity and MR Imaging of Tumors

Purpose: This study was performed to compare the cytotoxicity and magnetic resonance (MR) contrast in diverse cultured cells and xenograft tumors models of two ultra-small superparamagnetic iron oxides (USPIOs), thermally cross-linked superparamagnetic iron oxide nanoparticles (TCL-SPION) and monocrystalline iron oxide nanoparticles (MION-47). Materials and methods: Transmission electron microscopy (TEM) images and R2 relaxivity values of the TCL-SPION and MION-47 were obtained and the cell viability and cell growth velocity of treated and untreated human fibroblasts and human umbilical vein endothelial cells (HUVEC) were evaluated. The effect of TCL-SPION and MION-47 on the secretion of interlukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), the production of nitric oxides and the mitochondrial membrane potentials in murine macrophage cells (RAW264.7) was compared. Human hepatocellular carcinoma cells (HepG2, 5x105) were subcutaneously injected into nude mice (BALB/c) and in vivo MR imaging of tumors before and after injection with TCL-SPION or MION-47 (12.5 mg Fe/kg) was performed on a 1.5 Tesla MRI scanner. Results: On TEM images, the average core diameter of TCL-SPION was 9 nm whereas that of MION-47 was 5 nm. TCL- SPION (345.0 ± 6.2 mM-1sec-1) had higher relaxivity (R2) than MION-47 (130.7 ± 1.1 mM-1sec-1). Significant changes in cell viability and growth were not found in human fibroblasts and HUVEC exposed to TCL-SPION and MION-47. However, IL-6 and TNF-α secretions increased dose-dependently and significantly in the macrophages treated with MION-47 or TCL-SPION. TCL-SPION had a lower stimulatory effect on IL-6 secretions than did MION-47 (P <0.05) and nitric oxides were produced in the macrophages by MION-47 but not TCL-SPION. A change in the mitochondrial membrane potential of the macrophages was observed 24 hours after the exposure, and MION-47 induced more collapses of the mitochondrial membrane potential than did TCL-SPION. In the in vivo MR imaging, 33.0 ± 1.3% and 7.5 ± 0.4% signal intensity decrease on T2*-weighted images was observed in the tumors injected with TCL-SPION and MION-47, respectively. Conclusion: Due to the modified surface properties and larger core size of its iron oxide nanoparticles, TCL-SPION achieves lower cytotoxicity and better tumor MR contrast than MION-47. Our study suggests that TCL-SPION may be used as a new platform for tumor imaging and therapy monitoring.

[1]  James B. Mitchell,et al.  Estimation of tumor microvessel density by MRI using a blood pool contrast agent. , 2009, International journal of oncology.

[2]  K. Landfester,et al.  The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. , 2010, Biomaterials.

[3]  K. Chang,et al.  Cervical lymph node metastases: MR imaging of gadofluorine M and monocrystalline iron oxide nanoparticle-47 in a rabbit model of head and neck cancer. , 2006, Radiology.

[4]  Vincent Castranova,et al.  Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling , 2009, Particle and Fibre Toxicology.

[5]  C. R I S T I N,et al.  Oxidative Stress Induced by Zero-Valent Iron Nanoparticles and Fe ( II ) in Human Bronchial Epithelial Cells , 2009 .

[6]  Do Kyung Kim,et al.  Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. , 2006, Journal of the American Chemical Society.

[7]  Woo Kyung Moon,et al.  Integrin-targeting thermally cross-linked superparamagnetic iron oxide nanoparticles for combined cancer imaging and drug delivery , 2010, Nanotechnology.

[8]  Hye Won Kim,et al.  TCL-SPION-enhanced MRI for the detection of lymph node metastasis in murine experimental model. , 2011, Academic radiology.

[9]  C. Corot,et al.  Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. , 1996, Academic radiology.

[10]  Fabian Kiessling,et al.  FMN-coated fluorescent iron oxide nanoparticles for RCP-mediated targeting and labeling of metabolically active cancer and endothelial cells. , 2011, Biomaterials.

[11]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[12]  R. Weissleder,et al.  Imaging inflammation of the pancreatic islets in type 1 diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Steven C.R. Williams,et al.  Proc. Intl. Soc. Mag. Reson. Med. , 2012 .

[14]  Jing Lin,et al.  Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy. , 2011, Biomaterials.

[15]  In-Kyu Park,et al.  Hybrid superparamagnetic iron oxide nanoparticle-branched polyethylenimine magnetoplexes for gene transfection of vascular endothelial cells. , 2010, Biomaterials.

[16]  Z. Fayad,et al.  Clearance of Iron Oxide Particles in Rat Liver: Effect of Hydrated Particle Size and Coating Material on Liver Metabolism , 2006, Investigative radiology.

[17]  W. Moon,et al.  Magnetic resonance imaging and biological properties of pancreatic islets labeled with iron oxide nanoparticles , 2009, NMR in biomedicine.

[18]  W. Moon,et al.  The effects of clinically used MRI contrast agents on the biological properties of human mesenchymal stem cells , 2010, NMR in biomedicine.

[19]  Jinwoo Cheon,et al.  Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. , 2005, Journal of the American Chemical Society.

[20]  Kan Wang,et al.  Biocompatibility of hydrophilic silica-coated CdTe quantum dots and magnetic nanoparticles , 2011, Nanoscale research letters.

[21]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  R Weissleder,et al.  Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties , 1993, Magnetic resonance in medicine.

[23]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[24]  Vasilis Ntziachristos,et al.  Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. , 2003, Radiology.

[25]  M. Bock,et al.  Physical and Biological Characterization of Superparamagnetic Iron Oxide- and Ultrasmall Superparamagnetic Iron Oxide-Labeled Cells: A Comparison , 2005, Investigative radiology.

[26]  Ralph Weissleder,et al.  Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. , 2002, Academic radiology.

[27]  S. Hussain,et al.  Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging , 2001, European Radiology.

[28]  K C Zoon,et al.  Interferons and their actions. , 1987, Annual review of biochemistry.

[29]  Y. Jeong,et al.  Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. , 2011, Small.

[30]  T. R. Pisanic,et al.  Intracellular nanoparticle coating stability determines nanoparticle diagnostics efficacy and cell functionality. , 2010, Small.

[31]  Anders M. Dale,et al.  Repeated fMRI Using Iron Oxide Contrast Agent in Awake, Behaving Macaques at 3 Tesla , 2002, NeuroImage.

[32]  S. Choi,et al.  Contrast-Enhanced MR Imaging of Lymph Nodes in Cancer Patients , 2010, Korean journal of radiology.

[33]  Philippe Robert,et al.  Recent advances in iron oxide nanocrystal technology for medical imaging. , 2006, Advanced drug delivery reviews.

[34]  V. Lakics,et al.  Lipopolysaccharide and ceramide use divergent signaling pathways to induce cell death in murine macrophages. , 1998, Journal of immunology.

[35]  A. Heerschap,et al.  Assessment of Blood Hemodynamics by USPIO-Induced R1 Changes in MRI of Murine Colon Carcinoma , 2010, Applied magnetic resonance.

[36]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[37]  Sangjin Park,et al.  Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. , 2007, Journal of the American Chemical Society.

[38]  Stefaan C De Smedt,et al.  High intracellular iron oxide nanoparticle concentrations affect cellular cytoskeleton and focal adhesion kinase-mediated signaling. , 2010, Small.

[39]  Gang Bao,et al.  Coating thickness of magnetic iron oxide nanoparticles affects R2 relaxivity , 2007, Journal of magnetic resonance imaging : JMRI.